Who are Intravenous Infusion of Aclasta®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Boniva, Zometa, Fosamax, Aredia, ZA, Alendronate and Zoledronate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-infusion-of-aclasta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intravenous Infusion of Aclasta® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Infusion of Aclasta® (Intravenous Infusion of Aclasta®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Oncology.

phase 2 Bisphosphonate Farnesyl pyrophosphate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Infusion of Aclasta® (Intravenous Infusion of Aclasta®) — AUVA Traumazentrum Vienna Site UKH Meidling. Bisphosphonate that inhibits osteoclast-mediated bone resorption

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous Infusion of Aclasta® TARGET	Intravenous Infusion of Aclasta®	AUVA Traumazentrum Vienna Site UKH Meidling	phase 2	Bisphosphonate	Farnesyl pyrophosphate synthase
Boniva	IBANDRONIC ACID	Hoffmann La Roche	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	2003-01-01
Zometa	ZOLEDRONIC ACID	Novartis	marketed	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	marketed	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01
Aredia	PAMIDRONIC ACID		marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	1991-01-01
ZA	ZA	Merck Sharp & Dohme LLC	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase (indirect); hydroxyapatite in bone (binding site)
Alendronate and Zoledronate	Alendronate and Zoledronate	National Taiwan University Hospital	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase (mevalonate pathway); hydroxyapatite binding

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-12-05 — Fosamax · 9592195 · US

Sponsor landscape (Bisphosphonate class)

· 2 drugs in this class
Amgen · 2 drugs in this class
National Taiwan University Hospital · 2 drugs in this class
Sanofi · 2 drugs in this class
Ludwig-Maximilians - University of Munich · 2 drugs in this class
Chinese University of Hong Kong · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Aarhus University Hospital · 1 drug in this class
Eisai Inc. · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Infusion of Aclasta® — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-infusion-of-aclasta. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab